Invention Grant
- Patent Title: TRK inhibitors useful as anticancer drugs
-
Application No.: US17273046Application Date: 2019-09-03
-
Publication No.: US11952364B2Publication Date: 2024-04-09
- Inventor: Boyu Zhong , Tony Yantao Zhang , Yiju Cao , Guangming Chen
- Applicant: TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED
- Applicant Address: CN Shanghai
- Assignee: TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED
- Current Assignee: TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED
- Current Assignee Address: CN Shanghai
- Agency: LADAS & PARRY LLP
- Priority: CN 1811019556.X 2018.09.03
- International Application: PCT/CN2019/104218 2019.09.03
- International Announcement: WO2020/048455A 2020.03.12
- Date entered country: 2021-03-03
- Main IPC: C07D401/14
- IPC: C07D401/14 ; A61K31/4439 ; A61K45/06 ; A61P35/00 ; C07D487/04

Abstract:
A group of tropomyosin receptor kinase inhibitors including an amido-phenoxy-indazole structure fragment. These compounds show potent inhibitory effects on various oncogenic kinases, especially TRK, and thus can be used to treat tumors or cancers.
Public/Granted literature
- US20220388983A1 TRK INHIBITORS USEFUL AS ANTICANCER DRUGS Public/Granted day:2022-12-08
Information query